| Assessment Status |
Rapid Review Complete |
| HTA ID |
25004 |
| Drug |
Ruxolitinib |
| Brand |
Opzelura® |
| Indication |
Ruxolitinib (Opzelura®) is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. |
| Rapid review commissioned |
09/01/2025 |
| Rapid review completed |
17/02/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ruxolitinib cream for this indication compared with the current standard of care. |
